^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    FoundationFocus CDxBRCA Assay

    Company:
    Roche
    Type:
    FDA Approved
    Related tests:
    4years
    A profile on the FoundationFocus CDxBRCA tests. (PubMed, Expert Rev Mol Diagn)
    "The Foundation Focus test began as a next-generation sequencing assay capable of detecting germline (gBRCA) and somatic (sBRCA) mutations that predict response to rucaparib treatment. The addition of LOH to the assay was validated by a clinical trial supporting expansion of the Rucaparib FDA label to include maintenance of chemotherapy response."
    Journal
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • HRD • HRD + BRCA1 mutation • BRCA1 mutation + BRCA2 mutation
    |
    FoundationFocus CDxBRCA Assay
    |
    Rubraca (rucaparib)